AbbVie completes $31.26/share ImmunoGen acquisition; reaffirms FY2024 EPS guidance with $0.42 dilution

AbbVie Inc.

Acquired all outstanding ImmunoGen shares for $31.26 each; ImmunoGen ceases trading on NASDAQ.
Adds ELAHERE (FRα-positive ovarian cancer ADC) and pipeline assets including IMGN-151 and pivekimab sunirine.
Reaffirms full-year 2024 adjusted diluted EPS guidance of $11.05-$11.25, now including $0.42 dilution from ImmunoGen and pending Cerevel.
Updates Q1 2024 adjusted EPS guidance to $2.26-$2.30 from $2.30-$2.34 due to $0.04 dilutive impact from ImmunoGen.
Expects the acquisition to be accretive to diluted EPS beginning in 2027 and significantly accretive over long term.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.